Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

CME/CE

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Videos

Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center, discusses the clinical trials that influenced plasminogen's (Ryplazim; Kedrion Biopharma) FDA approval, as well as details valuable information for the treatment of patients with plasminogen deficiency.

Patients With Plasminogen Deficiency Should Receive Care at Hemophilia Treatment Centers: Dr Amy Shapiro

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

Expert speakers at the American Thoracic Society (ATS) 2024 international conference share their favorite parts of the event and the key takeaways they will leave the conference with.

ATS 2024: Building Real-World Data to Inform Clinical Practice and More Takeaways

Articles

Experts warn of insufficient support for patients amid surge in prescriptions for weight loss; new Florida law will allow C-sections in clinics; focus shifts to amending international health regulations for pandemic preparedness.

What We’re Reading: Obesity Specialist Shortage; Out-of-Hospital C-Sections; Ramping Up Pandemic Preparedness 

Among the many topics discussed at the American Thoracic Society 2024 International Conference (ATS 2024), the majority touched on barriers to health equity and access, regardless of the key focus of each talk or study. Experts examined this within the field, emphasizing the importance of enhancing data diversity, modernizing diagnostic tools, and revising regulatory standards to promote equitable health outcomes for diverse populations.

ATS 2024 Review: Innovative Treatments and Health Equity Take Center Stage

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About Us

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiovascular

Chronic Kidney Disease

Diabetes

Heart Failure

Type 1 Diabetes

Cardiorenalmetabolic

Alopecia

Atopic Dermatitis

Psoriasis

Dermatology

Hemophilia

Rare Blood

Hematology

Liver

Hepatology

Autoimmune

Inflammation

Lupus

Myasthenia Gravis

Immunology

COVID-19

Vaccines

Infectious Disease

Major Depressive Disorder

Sleep

Mental Health

Duchenne Muscular Dystrophy

Epilepsy

Multiple Sclerosis

Parkinson Disease

Neurology

Breast Cancer

Cholangiocarcinoma

Colorectal Cancer

DLBCL

Immuno-Oncology

Leukemia and Lymphoma

Lung Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Non–Small Cell Lung Cancer

Ovarian Cancer

Prostate Cancer

Skin Cancer

Oncology

Ophthalmology

COPD

Pulmonary Arterial Hypertension

Pulmonology

Spinal Muscular Atrophy

Rare Disease

Asthma

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Employers

Medicare

Reimbursement

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

1rem

Summary of the CLEAR Outcomes Trial